La presente informativa è resa, anche ai sensi dell’art. 13 del D. Lgs. 196/2003 “Codice in materia di protezione dei dati personali” (“Codice Privacy”) 
e degli artt. 13 e 14 del Regolamento (UE) 2016/679 (“GDPR”), a coloro che si collegano alla presente edizione online del giornale Tribuna Economica di proprietà di AFC Editore Soc. Coop. 

Leggi di più

The European Investment Bank (EIB) has signed a EUR 50m loan with Ferrer, a Spanish pharmaceutical company, aimed at supporting its research activities. The EIB loan to Ferrer will finance the company’s research activities in the fields of inflammatory diseases, diagnostics, orphan diseases, biotherapeutics and development in

cardiovascular, respiratory and other therapeutic areas such as central nervous systems.

The RDI activities will be carried out in Barcelona and will be implemented until 2017. The project will strengthen the company’s position in its core market by accelerating its RDI programmes. In addition, the research activities target areas of significant unmet medical need and improvement of patients’ quality of life.

This long-term loan reflects the EIB’s commitment to supporting RDI and promoting the development of midcap companies. By financing these RDI investments, the EIB will help to underpin the company’s sustainable growth and employment.


Ferrer’s R&D project is supported by “InnovFin – EU Finance for Innovators”, a new range of EIB Group products which benefit from the financial support of the European Union under Horizon 2020 Financial Instruments and are designed to facilitate access to finance for innovative businesses.